Regeneron beats quarterly profit estimates on Dupixent strength

Jan 30 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals beat analysts' estimate for fourth-quarter profit on Friday, ...
Investor's Business Daily on MSN

Sanofi edges higher as immunology powerhouse, Dupixent, wallops forecasts

Sanofi stock edged higher Thursday after its immunological powerhouse, Dupixent, handily beat Wall Street's fourth-quarter ...

Amgen gives up on its once-prized eczema drug

The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of ...
BioPharma Dive

Corvus shares nearly triple on positive data for eczema pill

While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed ...
STAT

Corvus pill shows promise in early-stage eczema trial

After eight weeks, 75% of participants treated with the Corvus pill, called soquelitinib, achieved at least a 75% improvement ...
Seeking Alpha

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing ...
JD Supra

First Dupixent Lawsuit Filed Over Fatal Lymphoma: What It Means for Patients and Families

The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...
Benzinga.com

Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), which will be presented at the Fall Clinical Dermatology Conference. The ...
Reuters

Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

PARIS (Reuters) - The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron , the ...
U.S. News & World Report

Sanofi Sheds $13 Billion in Value on Weak Trial Results for Eczema Drug

LONDON (Reuters) -Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after late-stage trial data for its experimental inflammatory ...